Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

Nancy J. Sullivan, Thomas W. Geisbert, Joan B. Geisbert, Ling Xu, Zhi-yong Yang, Mario Roederer, Richard A. Koup, Peter B. Jahrling and Gary J. Nabel ()
Additional contact information
Nancy J. Sullivan: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Thomas W. Geisbert: United States Army Medical Research Institute of Infectious Diseases
Joan B. Geisbert: United States Army Medical Research Institute of Infectious Diseases
Ling Xu: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Zhi-yong Yang: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Mario Roederer: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Richard A. Koup: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Peter B. Jahrling: United States Army Medical Research Institute of Infectious Diseases
Gary J. Nabel: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Nature, 2003, vol. 424, issue 6949, 681-684

Abstract: Abstract Containment of highly lethal Ebola virus outbreaks poses a serious public health challenge. Although an experimental vaccine has successfully protected non-human primates against disease1, more than six months was required to complete the immunizations, making it impractical to limit an acute epidemic. Here, we report the development of accelerated vaccination against Ebola virus in non-human primates. The antibody response to immunization with an adenoviral (ADV) vector encoding the Ebola glycoprotein (GP) was induced more rapidly than with DNA priming and ADV boosting, but it was of lower magnitude. To determine whether this earlier immune response could nonetheless protect against disease, cynomolgus macaques were challenged with Ebola virus after vaccination with ADV–GP and nucleoprotein (NP) vectors. Protection was highly effective and correlated with the generation of Ebola-specific CD8+ T-cell and antibody responses. Even when animals were immunized once with ADV–GP/NP and challenged 28 days later, they remained resistant to challenge with either low or high doses of virus. This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses.

Date: 2003
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/nature01876 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:424:y:2003:i:6949:d:10.1038_nature01876

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature01876

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().